SciBase Holding AB (STO: SCIB), a developer of AI-based diagnostic solutions for skin disorders, announced on Monday that new research presented at the Society for Investigative Dermatology Annual Meeting showed that its Nevisense platform can detect and quantify age-related skin barrier changes using proprietary Electrical Impedance Spectroscopy technology.
The study, conducted by Professor Abuabara and Dr. Zhu at University of California, San Francisco, compared EIS measurements between younger adults with a mean age of 25.9 years and older adults with a mean age of 79.1 years.
Researchers analysed 700 parameters from each Nevisense measurement and developed a composite barrier score that identified 35 age-associated EIS features in the forearm. The score demonstrated a strong correlation with age, with a Spearman rho of 0.69, indicating the technology can detect subtle changes in skin architecture and composition linked to ageing.
The study also found that analysing specific EIS features provided a more sensitive assessment of age-related skin barrier changes than standard summary values.
SciBase said the findings expand Nevisense's potential applications beyond melanoma detection and atopic dermatitis assessment into geriatric dermatology and longevity science. The company said further validation studies are planned to refine the composite barrier score for clinical and research use.
Tenaya Therapeutics reports interim RIDGE-1 data showing reduced arrhythmia burden with TN-401
SN BioScience reports first patient dosed in global Phase 1b/2 clinical trial of SNB-101
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
AstraZeneca reports survival gains in Phase III bladder cancer trial
Ipsen presents Phase II corabotase data at SCALE 2026 symposium
SOPHiA GENETICS and Synnovis partner to expand NHS liquid biopsy testing
Voyager Technologies secures ISS mission management contract with Exobiosphere
WuXi Biologics named in 2026 Dow Jones Best-in-Class World Index and Emerging Markets Index
Clearway Health recognised with 2026 Great Place To Work Certification for fourth consecutive year
Servier's Emi-Le receives US FDA breakthrough therapy designation for adenoid cystic carcinoma
Insilico Medicine enters strategic collaboration agreement with Ribo
Bavarian Nordic secures USD97m US vaccine contract expansion and raises 2026 outlook
Ranok Therapeutics reports positive Phase 1a clinical results for KRAS G12D inhibitor RNK08954